A Systematic Review of Reported Outcomes in ADPKD Studies-Reference-Cited by-同舟云学术

A Systematic Review of Reported Outcomes in ADPKD Studies

Published:2022-09 Issue:9 Volume:7 Page:1964-1979
ISSN:2468-0249
Container-title:Kidney International Reports
language:en
Short-container-title:Kidney International Reports

Author:

Jdiaa Sara S.,Husainat Nedaa M.,Mansour Razan^ORCID,Kalot Mohamad A.,McGreal Kerri,Chebib Fouad T.,Perrone Ronald D.^ORCID,Yu Alan^ORCID,Mustafa Reem A.

Publisher

Elsevier BV

Subject

Nephrology

Reference198 articles.

1. Autosomal dominant polycystic kidney disease: the changing face of clinical management;Ong;Lancet,2015

2. Renal replacement therapy for autosomal dominant polycystic kidney disease (ADPKD) in Europe: prevalence and survival-an analysis of data from the ERA-EDTA Registry;Spithoven;Nephrol Dial Transplant,2014

3. Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: improving Global Outcomes (KDIGO) Controversies Conference;Chapman;Kidney Int,2015

4. Recent advances in the management of autosomal dominant polycystic kidney disease;Chebib;Clin J Am Soc Nephrol,2018

5. Autosomal dominant polycystic kidney disease;Torres;Lancet,2007

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Determinants of Disease Progression in Autosomal Dominant Polycystic Kidney Disease;Journal of Personalized Medicine;2024-09-02

2. A Primer for Utilizing Deep Learning and Abdominal MRI Imaging Features to Monitor Autosomal Dominant Polycystic Kidney Disease Progression;Biomedicines;2024-05-20

3. Pain and Health-Related Quality of Life in Autosomal Dominant Polycystic Kidney Disease: Results from a National Patient-Powered Registry;Kidney Medicine;2024-05

4. The Role of the L-Arginine–Nitric Oxide Molecular Pathway in Autosomal Dominant Polycystic Kidney Disease;Journal of Personalized Medicine;2024-03-11

5. Estimating risk of rapid disease progression in pediatric patients with autosomal dominant polycystic kidney disease: a randomized trial of tolvaptan;Pediatric Nephrology;2023-12-13